Agenus Inc. Stock News

Here's three penny stocks to watch right now The post 3 Penny Stocks to Add to Your Watch List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Lynch & Associates IN grew its stake in Agenus Inc. (NASDAQ:AGEN) by 25.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,493 shares of the biotechnology companys stock after purchasing an additional 5,393 shares during the period. Lynch & Associates INs holdings []

California State Teachers Retirement System increased its holdings in shares of Agenus Inc. (NASDAQ:AGEN) by 14.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 271,826 shares of the biotechnology companys stock after acquiring an additional 34,694 shares during the quarter. California State Teachers Retirement Systems holdings in Agenus were worth $1,492,000 as of []

Agenus Inc. (NASDAQ:AGEN) price on Thursday, November 18, rose 1.42% above its previous days close as an upside momentum from buyers pushed the stocks value to $3.58. A look at the stocks price movement, the close in the last trading session was $3.53, moving within a range at $3.41 and $3.68. The beta value (5-Year Honey At Agenus Inc. (AGEN) Is Worth Your Money Read More »

Agenus Inc. (NASDAQ:AGEN) Analysts at William Blair decreased their FY2021 EPS estimates for Agenus in a research note issued to investors on Monday, November 15th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($0.11) per share for the year, down from their previous forecast of ($0.10). William []

Adaptimmune Therapeutics and Agenus are having a tough go of it in the final quarter of 2021.

Equities research analysts forecast that Agenus Inc. (NASDAQ:AGEN) will announce ($0.12) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Agenus earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.16). Agenus posted earnings of ($0.20) per share in the []

In a Phase I study across nine tumor types, Agenus Inc's (NASDAQ: AGEN) CTLA-4 drug AGN1181 posted one complete response and three partial responses (PRs) as a monotherapy, according to data prese

Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines desig

Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Info

Biotech stocks that fall hard on bad news can rebound in a flash.

The company's experimental anti-PD1 drug hit a wall.

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines

But those wins probably won't be all that big.